Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Soleno Therapeutics Inc (SLNO)

Soleno Therapeutics Inc (SLNO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Thinking about buying stock in Irving Resources, Soligenix, Exela Technologies, Soleno Therapeutics, or Onconova Therapeutics?

/PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for IRV, SNGX, XELA, SLNO, and ONTX.

IRVRF : 1.4000 (+1.45%)
IRV.CN : 1.710 (unch)
ONTX : 7.00 (-3.71%)
SLNO : 1.0800 (+0.93%)
SNGX : 1.1200 (-6.67%)
XELA : 1.2800 (-6.57%)
Soleno Therapeutics Receives Orphan Drug Designation from FDA for Diazoxide Choline for the Treatment of Glycogen Storage Disease Type 1a

Soleno Therapeutics, Inc. ("Soleno") (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that the U.S. Food and...

SLNO : 1.0800 (+0.93%)
Soleno Therapeutics to Host Webinar Highlighting DCCR for Treatment of Prader-Willi Syndrome at European Congress on Endocrinology 2021

Soleno Therapeutics, Inc. ("Soleno") (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that the Company will host...

SLNO : 1.0800 (+0.93%)
Soleno Therapeutics to Participate in the Oppenheimer Rare & Orphan Disease Summit

Soleno Therapeutics, Inc. ("Soleno") (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D.,...

SLNO : 1.0800 (+0.93%)
Thinking about buying stock in LightPath Technologies, Minerva Neurosciences, Cerecor, Eloxx Pharmaceuticals, or Soleno Therapeutics?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for LPTH, NERV, CERC, ELOX, and SLNO.

ELOX : 2.08 (unch)
NERV : 2.63 (-1.87%)
CERC : 3.67 (+4.26%)
LPTH : 2.48 (+2.06%)
SLNO : 1.0800 (+0.93%)
Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2021 Financial Results

Soleno Therapeutics, Inc. ("Soleno") (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and...

SLNO : 1.0800 (+0.93%)
Soleno Therapeutics Announces Presentation of Positive Behavioral Data from Ongoing Extension Study of DCCR for Treatment of Prader-Willi Syndrome

Results Show Improvement in Multiple Behavioral Domains Following Treatment with DCCR

SLNO : 1.0800 (+0.93%)
Soleno Therapeutics Participates in Prader-Willi Syndrome (PWS) DCCR Town Hall

Soleno Therapeutics, Inc. ("Soleno") (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D.,...

SLNO : 1.0800 (+0.93%)
Soleno Therapeutics (SLNO) Enters Oversold Territory

Soleno Therapeutics (SLNO) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

SLNO : 1.0800 (+0.93%)
Pacira (PCRX) Gets FDA Nod for Exparel in Pediatric Patients

The FDA approves Pacira's (PCRX) Exparel for use in patients aged six years and older for single-dose infiltration to produce postsurgical local analgesia.

PCRX : 59.64 (-1.34%)
CANF : 2.28 (-2.15%)
OPHLF : 21.5000 (-5.29%)
SLNO : 1.0800 (+0.93%)
Catalyst (CPRX) Beats on Q4 Earnings, Revenues Rise Y/Y

Catalyst's (CPRX) earnings and revenues beat estimates in the fourth quarter of 2020.

ZTS : 185.39 (-0.56%)
CPRX : 5.73 (unch)
CTLT : 108.61 (-1.76%)
SLNO : 1.0800 (+0.93%)
Soleno to Participate in the 31st Annual Oppenheimer Healthcare Conference

Soleno Therapeutics, Inc. ("Soleno") (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D.,...

SLNO : 1.0800 (+0.93%)
Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Soleno Therapeutics, Inc. (SLNO) and Encourages Investors to Contact the Firm

NEW YORK, NY / ACCESSWIRE / March 9, 2021 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Soleno Therapeutics, Inc. ("Soleno" or "the Company") (NASDAQ:SLNO)....

SLNO : 1.0800 (+0.93%)
Soleno Therapeutics (SLNO) Is in Oversold Territory: What's Next?

Soleno Therapeutics (SLNO) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock

SLNO : 1.0800 (+0.93%)
Soleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome

Soleno Therapeutics, Inc. ("Soleno") (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided an update following recent...

SLNO : 1.0800 (+0.93%)
Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2020 Financial Results

Soleno Therapeutics, Inc. ("Soleno") (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update and announced...

SLNO : 1.0800 (+0.93%)
Soleno Therapeutics Announces Collaboration with Vanderbilt University to Discover and Develop Next Generation K(ATP) Channel Activators for the Treatment of Rare Diseases

Soleno Therapeutics, Inc. ("Soleno") (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it has signed a collaboration...

SLNO : 1.0800 (+0.93%)
Soleno Therapeutics Provides Recap of Key Opinion Leader Webinar on DCCR for Treatment of Prader-Willi Syndrome

Soleno Therapeutics, Inc. ("Soleno") (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today hosted a Key Opinion Leader (KOL)...

SLNO : 1.0800 (+0.93%)
Soleno Therapeutics to Host Key Opinion Leader Meeting on DCCR for the Treatment of Prader-Willi Syndrome

Soleno Therapeutics, Inc. ("Soleno") (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced it will host a Key Opinion...

SLNO : 1.0800 (+0.93%)
Soleno Therapeutics to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference

Soleno Therapeutics, Inc. ("Soleno") (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that management will present...

SLNO : 1.0800 (+0.93%)

Barchart Exclusives

The Bullish Pattern In Natural Gas Continues
At the end of June 2020, natural gas fell to the lowest price of this century when it reached a twenty-five-year low. In June 2021, the price action has been bullish. Read more

Barchart Futures Commentary

Barchart Futures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar